Drug Profile
Iscalimab - Novartis
Alternative Names: CFZ-533; NVP-CFZ533; OM11-62-MFLatest Information Update: 02 Jan 2024
Price :
$50
*
At a glance
- Originator Novartis; XOMA
- Developer Novartis
- Class Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Monoclonal antibodies; Urologics
- Mechanism of Action CD40 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Graves' disease; Hidradenitis suppurativa; Liver transplant rejection; Lupus nephritis; Myasthenia gravis; Sjogren's syndrome; Systemic lupus erythematosus; Type 1 diabetes mellitus
- Phase I/II Renal transplant rejection
- No development reported Rheumatoid arthritis
Most Recent Events
- 10 Nov 2023 Efficacy and adverse events data from a phase IIb TWINSS trial in Sjogren's syndrome presented at the ACR Convergence 2023
- 28 Jul 2023 Discontinued - Phase-II for Liver transplant rejection (Combination therapy) in Italy, USA, Netherlands, Argentina (SC) (Novartis pipeline, July 2023)
- 28 Jul 2023 Discontinued - Phase-II for Liver transplant rejection (Combination therapy) in USA, Netherlands, Italy, Argentina (IV) before July 2023 (Novartis pipeline, July 2023)